Pathstone Holdings
NBIX icon

Pathstone Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Pathstone Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
13,005
+1,148
+10% +$170K 0.01% 1062
2026
Q1 		$1.56M Sell
11,857
-70
-0.6% -$9.29K 0.01% 1158
2025
Q4 		$1.69M Buy
11,927
+664
+6% +$96.2K 0.01% 1122
2025
Q3 		$1.58M Buy
11,263
+8
+0.1% +$1.08K 0.01% 1164
2025
Q2 		$1.41M Buy
11,255
+2,802
+33% +$321K 0.01% 1200
2025
Q1 		$935K Sell
8,453
-374
-4% -$47.4K ﹤0.01% 1417
2024
Q4 		$1.2M Buy
8,827
+1,980
+29% +$245K 0.01% 1263
2024
Q3 		$789K Sell
6,847
-2,696
-28% -$370K ﹤0.01% 1495
2024
Q2 		$1.31M Buy
9,543
+4,206
+79% +$577K 0.01% 1162
2024
Q1 		$736K Sell
5,337
-1,031
-16% -$141K ﹤0.01% 1480
2023
Q4 		$839K Buy
+6,368
New +$733K ﹤0.01% 1172

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pathstone Holdings's NBIX Position: Q2 2026 in Review

Pathstone Holdings increased its Neurocrine Biosciences (NBIX) stake by 9.7% in Q2 2026, buying an estimated $170K and bringing the position to 13,005 shares worth $2.19M. The position accounts for 0.01% of the portfolio, ranked #1062.

Pathstone Holdings first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Pathstone Holdings held 13,005 shares of Neurocrine Biosciences worth $2.19M as of Q2 2026.
  • Pathstone Holdings bought 1,148 Neurocrine Biosciences shares in Q2 2026, an estimated $170K.
  • Neurocrine Biosciences made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1062 holding.
  • Pathstone Holdings first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.